Robert W. Baird reaffirmed their hold rating on shares of DexCom, Inc. (NASDAQ:DXCM) in a report published on Sunday morning. They currently have a $79.00 price objective on the medical device company’s stock.

Other equities research analysts also recently issued reports about the company. Piper Jaffray Companies reaffirmed a buy rating and issued a $78.00 price target on shares of DexCom in a research report on Wednesday, July 12th. Oppenheimer Holdings, Inc. set a $92.00 price target on DexCom and gave the company a buy rating in a research report on Wednesday, August 2nd. BidaskClub downgraded DexCom from a sell rating to a strong sell rating in a research report on Tuesday, August 1st. BMO Capital Markets reaffirmed an outperform rating and issued a $90.00 price target (down from $105.00) on shares of DexCom in a research report on Tuesday, August 8th. Finally, Zacks Investment Research raised DexCom from a sell rating to a hold rating in a research report on Monday, August 14th. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. DexCom currently has an average rating of Buy and a consensus price target of $87.64.

DexCom (DXCM) opened at 71.26 on Friday. DexCom has a 1-year low of $57.68 and a 1-year high of $95.40. The firm’s market cap is $6.17 billion. The company has a 50 day moving average price of $71.90 and a 200 day moving average price of $74.32.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.07. The company had revenue of $170.60 million for the quarter, compared to the consensus estimate of $166.54 million. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The firm’s revenue was up 24.3% compared to the same quarter last year. During the same period last year, the business posted ($0.24) earnings per share. On average, equities research analysts forecast that DexCom will post ($0.77) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “DexCom, Inc. (DXCM) Receives “Hold” Rating from Robert W. Baird” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/11/dexcom-inc-dxcm-receives-hold-rating-from-robert-w-baird.html.

In other DexCom news, EVP Richard Doubleday sold 1,635 shares of the firm’s stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $75.26, for a total transaction of $123,050.10. Following the completion of the transaction, the executive vice president now owns 72,395 shares in the company, valued at $5,448,447.70. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Steven Robert Pacelli sold 1,450 shares of the firm’s stock in a transaction dated Friday, June 23rd. The stock was sold at an average price of $78.19, for a total transaction of $113,375.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,979 shares of company stock valued at $1,646,805. Corporate insiders own 1.70% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Capstone Asset Management Co. bought a new position in shares of DexCom in the first quarter valued at approximately $213,000. DUPONT CAPITAL MANAGEMENT Corp bought a new position in shares of DexCom in the first quarter valued at approximately $270,000. Sumitomo Mitsui Asset Management Company LTD raised its stake in shares of DexCom by 14.7% in the first quarter. Sumitomo Mitsui Asset Management Company LTD now owns 6,768 shares of the medical device company’s stock valued at $573,000 after acquiring an additional 868 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in shares of DexCom by 1.5% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 12,541 shares of the medical device company’s stock valued at $1,063,000 after acquiring an additional 186 shares during the last quarter. Finally, Great West Life Assurance Co. Can raised its stake in shares of DexCom by 6.4% in the first quarter. Great West Life Assurance Co. Can now owns 27,413 shares of the medical device company’s stock valued at $2,320,000 after acquiring an additional 1,647 shares during the last quarter.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Stock Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related stocks with our FREE daily email newsletter.